BR112022023928A2 - Uso de canabidiol para o tratamento do transtorno do espectro autista - Google Patents
Uso de canabidiol para o tratamento do transtorno do espectro autistaInfo
- Publication number
- BR112022023928A2 BR112022023928A2 BR112022023928A BR112022023928A BR112022023928A2 BR 112022023928 A2 BR112022023928 A2 BR 112022023928A2 BR 112022023928 A BR112022023928 A BR 112022023928A BR 112022023928 A BR112022023928 A BR 112022023928A BR 112022023928 A2 BR112022023928 A2 BR 112022023928A2
- Authority
- BR
- Brazil
- Prior art keywords
- cannabidiol
- autism spectrum
- spectrum disorder
- treatment
- individual
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 5
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 4
- 229950011318 cannabidiol Drugs 0.000 title abstract 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 4
- 230000006399 behavior Effects 0.000 abstract 1
- 208000013404 behavioral symptom Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Alternative & Traditional Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USO DE CANABIDIOL PARA O TRATAMENTO DO TRANSTORNO DO ESPECTRO AUTISTA. A presente invenção refere-se a um método de tratamento de um ou mais sintomas comportamentais do transtorno do espectro autista (TEA) em um indivíduo administrando por via transdérmica uma quantidade eficaz de canabidiol (CBD) ao indivíduo, de modo que um ou mais sintomas comportamentais do TEA sejam tratados no indivíduo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029899P | 2020-05-26 | 2020-05-26 | |
| PCT/IB2021/054543 WO2021240368A1 (en) | 2020-05-26 | 2021-05-25 | Treatment of autism spectrum disorder with cannabidiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023928A2 true BR112022023928A2 (pt) | 2022-12-27 |
Family
ID=76181180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023928A BR112022023928A2 (pt) | 2020-05-26 | 2021-05-25 | Uso de canabidiol para o tratamento do transtorno do espectro autista |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210369643A1 (pt) |
| EP (1) | EP4157236A1 (pt) |
| JP (1) | JP2023528354A (pt) |
| KR (1) | KR20230016003A (pt) |
| CN (1) | CN115803019A (pt) |
| AU (1) | AU2021281118A1 (pt) |
| BR (1) | BR112022023928A2 (pt) |
| CA (1) | CA3180027A1 (pt) |
| IL (1) | IL298443A (pt) |
| JO (1) | JOP20220310A1 (pt) |
| MX (1) | MX2022014912A (pt) |
| WO (1) | WO2021240368A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058102T2 (hu) | 2017-09-28 | 2022-07-28 | Zynerba Pharmaceuticals Inc | Fragilis X szindróma és autizmus kezelése kannabidiollal |
| CA3235677A1 (en) * | 2021-10-22 | 2023-04-27 | Joseph Palumbo | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2760460C (en) | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| GB2549277B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| CA3075122A1 (en) * | 2017-09-15 | 2019-03-21 | Zelda Therapeutics Operations Pty Ltd | Composition and method for treating autism |
| HUE058102T2 (hu) * | 2017-09-28 | 2022-07-28 | Zynerba Pharmaceuticals Inc | Fragilis X szindróma és autizmus kezelése kannabidiollal |
-
2021
- 2021-05-25 MX MX2022014912A patent/MX2022014912A/es unknown
- 2021-05-25 WO PCT/IB2021/054543 patent/WO2021240368A1/en active Application Filing
- 2021-05-25 KR KR1020227045634A patent/KR20230016003A/ko active Search and Examination
- 2021-05-25 IL IL298443A patent/IL298443A/en unknown
- 2021-05-25 BR BR112022023928A patent/BR112022023928A2/pt unknown
- 2021-05-25 CA CA3180027A patent/CA3180027A1/en active Pending
- 2021-05-25 JP JP2022572594A patent/JP2023528354A/ja active Pending
- 2021-05-25 US US17/329,570 patent/US20210369643A1/en active Pending
- 2021-05-25 EP EP21728651.7A patent/EP4157236A1/en active Pending
- 2021-05-25 JO JOP/2022/0310A patent/JOP20220310A1/ar unknown
- 2021-05-25 AU AU2021281118A patent/AU2021281118A1/en active Pending
- 2021-05-25 CN CN202180040289.8A patent/CN115803019A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210369643A1 (en) | 2021-12-02 |
| KR20230016003A (ko) | 2023-01-31 |
| CA3180027A1 (en) | 2021-12-02 |
| WO2021240368A1 (en) | 2021-12-02 |
| AU2021281118A1 (en) | 2023-01-05 |
| MX2022014912A (es) | 2023-01-04 |
| EP4157236A1 (en) | 2023-04-05 |
| CN115803019A (zh) | 2023-03-14 |
| JP2023528354A (ja) | 2023-07-04 |
| JOP20220310A1 (ar) | 2023-01-30 |
| IL298443A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023928A2 (pt) | Uso de canabidiol para o tratamento do transtorno do espectro autista | |
| CL2023000095A1 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
| BR112017028132A2 (pt) | métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula | |
| BR112017009004A2 (pt) | composições e métodos compreendendo bactérias para melhorar o comportamento em distúrbios do desenvolvimento neurológico | |
| BR112017007767A2 (pt) | canabidiol para uso, método para tratar um paciente que sofre de complexo esclerose tuberosa, e, composição. | |
| BR112016029226A2 (pt) | métodos e composições para o tratamento de úlceras | |
| BR112016029498A2 (pt) | canabidiol, método para tratamento de epilepsia, e, composição. | |
| BR112019001794A2 (pt) | composição de cannabis | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| MX2022012424A (es) | Tratamiento del sindrome del cromosoma x fragil con canabidiol. | |
| BR112015026258A2 (pt) | composições e agentes terapêuticos e imunomoduladores, e usos dos mesmos | |
| BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
| BRPI0417493B8 (pt) | uso de uma toxina botulínica para tratamento de distúrbios da pele | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| BR112022004175A2 (pt) | Tratamento de encefalopatia de syngap1 | |
| CO2018004684A2 (es) | Métodos para tratar la epilepsia | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
| JOP20210140A1 (ar) | معالجة متلازمة الحذف 22q11.2 بكانابيديول | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| BR112022026044A2 (pt) | Tratamento de síndrome do x frágil com canabidiol | |
| BR112022004302A2 (pt) | Anticorpos anti-il-27 e usos dos mesmos | |
| BR112022018055A2 (pt) | Carbonato de cálcio amorfo para tratamento de acidose. | |
| BR112019004906A2 (pt) | combinação incluindo abx196 para o tratamento de câncer |